Paul C. Ho

10.1k total citations · 2 hit papers
173 papers, 7.6k citations indexed

About

Paul C. Ho is a scholar working on Molecular Biology, Oncology and Biomedical Engineering. According to data from OpenAlex, Paul C. Ho has authored 173 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Molecular Biology, 28 papers in Oncology and 25 papers in Biomedical Engineering. Recurrent topics in Paul C. Ho's work include Sirtuins and Resveratrol in Medicine (16 papers), Metabolomics and Mass Spectrometry Studies (15 papers) and Coronary Interventions and Diagnostics (14 papers). Paul C. Ho is often cited by papers focused on Sirtuins and Resveratrol in Medicine (16 papers), Metabolomics and Mass Spectrometry Studies (15 papers) and Coronary Interventions and Diagnostics (14 papers). Paul C. Ho collaborates with scholars based in Singapore, United States and China. Paul C. Ho's co-authors include Hai‐Shu Lin, Ratha Mahendran, Niagara Muhammad Idris, Yong Zhang, Muthu Kumara Gnanasammandhan, Jing Zhang, Eric Chun Yong Chan, Kishore Kumar Pasikanti, Zhe Wang and Jinzhu Wu and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Nature Medicine.

In The Last Decade

Paul C. Ho

169 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers

2012 1.3k citations Paul C. Ho, Ratha Mahendran et al. profile →
Resveratrol for cancer therapy: Challenges and future perspectives

2021 334 citations Zhaowu Ma, Xiaoqiang Xiang et al. Cancer Letters profile →

Peers

Countries citing papers authored by Paul C. Ho

Since Specialization

Citations

This map shows the geographic impact of Paul C. Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul C. Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul C. Ho more than expected).

Fields of papers citing papers by Paul C. Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul C. Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul C. Ho. The network helps show where Paul C. Ho may publish in the future.

Co-authorship network of co-authors of Paul C. Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Paul C. Ho. A scholar is included among the top collaborators of Paul C. Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul C. Ho. Paul C. Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Physiologically-based pharmacokinetic modeling of rosuvastatin in Chinese: Predicting the impact of SLCO1B1 and ABCG2 genetic variants and hepatic impairment on drug exposure 2025 ·Journal of Pharmaceutical Sciences ·Longjie Li, Xinyan Zhu, Wei Xu, Qingfeng He, (unknown), Hai‐Shu Lin, (unknown), Paul C. Ho, Juan Xie, Xiaoqiang Xiang	0
2	Formulating 10-hydroxycamptothecin into nanoemulsion with functional excipient tributyrin: An innovative strategy for targeted hepatic cancer chemotherapy 2024 ·International Journal of Pharmaceutics ·Shili Yang, Hai‐Shu Lin, Li Zhang, Paul C. Ho	2
3	Extracellular vesicle-derived biomarkers in prostate cancer care: Opportunities and challenges 2024 ·Cancer Letters ·Xiaoxiao Wang, (unknown), (unknown), Yufei Wang, (unknown), Jiahui Yu, Zhaowu Ma, Paul C. Ho, Gautam Sethi, Xiaoguang Chen, Lingzhi Wang, Boon Cher Goh	3
4	Conjugating uncoupler compounds with hydrophobic hydrocarbon chains to achieve adipose tissue selective drug accumulation 2024 ·Scientific Reports ·(unknown), Zhi Song, Gopalakrishnan Venkatesan, Sergio Rodríguez‐Cuenca, James A. West, Shili Yang, Choon‐Hong Tan, Paul C. Ho, Julian L. Griffin, Antonio Vidal‐Puig, Marcella Bassetto, Thilo Hagen	0
5	Dried Blood Spots—A Platform for Therapeutic Drug Monitoring (TDM) and Drug/Disease Response Monitoring (DRM) 2023 ·European Journal of Drug Metabolism and Pharmacokinetics ·(unknown), Paul C. Ho	24
6	Abiotic dechlorination in the presence of ferrous minerals 2021 ·Journal of Contaminant Hydrology ·Charles E. Schaefer, Paul C. Ho, (unknown), Charles J. Werth	11
7	A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs 2018 ·Preprints.org ·Andrea L.A. Wong, Xiaoqiang Xiang, Pei Shi Ong, (unknown), Nicholas Syn, (unknown), Alan Prem Kumar, Wei Peng Yong, Gautam Sethi, Boon Cher Goh, Paul C. Ho, Lingzhi Wang	7
8	Correction: Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients 2014 ·PLoS ONE ·Lingzhi Wang, (unknown), Winnie Yeo, (unknown), (unknown), Jieying Amelia Lau, (unknown), Andrea Li‐Ann Wong, (unknown), Robert C. Lim, Soo Chin Lee, Paul C. Ho, How-Sung Lee, Anthony K.C. Chan, Sherry S. Ansher, Mark J. Ratain, Boon-Cher Goh	1
9	Gas Chromatography Time-Of-Flight Mass Spectrometry (GC-TOF-MS)-Based Metabolomics for Comparison of Caffeinated and Decaffeinated Coffee and Its Implications for Alzheimer’s Disease 2014 ·PLoS ONE ·Kai Chang, Paul C. Ho	29
10	An automated Pearson's correlation change classification (APC3) approach for GC/MS metabonomic data using total ion chromatograms (TICs) 2013 ·The Analyst ·(unknown), Kesavan Esuvaranathan, Paul C. Ho, Kishore Kumar Pasikanti, Eric Chun Yong Chan, Chun Wei Yap	1
11	Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography–tandem mass spectrometry 2011 ·Journal of Chromatography A ·Lingzhi Wang, (unknown), (unknown), (unknown), (unknown), Andrea Li‐Ann Wong, Sui Yung Chan, Boon-Cher Goh, Paul C. Ho	1
12	Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry 2010 ·Analytical and Bioanalytical Chemistry ·Kishore Kumar Pasikanti, (unknown), Shirong Cai, Ratha Mahendran, Kesavan Esuvaranathan, Paul C. Ho, Eric Chun Yong Chan	25
13	Integrin targeted drug and gene delivery 2010 ·Expert Opinion on Drug Delivery ·Zhe Wang, Wai‐Keung Chui, Paul C. Ho	34
14	A simple and sensitive HPLC-UV method for the quantification of piceatannol analog trans-3,5,3′,4′-tetramethoxystilbene in rat plasma and its application for a pre-clinical pharmacokinetic study 2009 ·Journal of Pharmaceutical and Biomedical Analysis ·Hai‐Shu Lin, Corrado Tringali, Carmela Spatafora, Wu Chun, Paul C. Ho	40
15	Determination of pterostilbene in rat plasma by a simple HPLC‐UV method and its application in pre‐clinical pharmacokinetic study 2009 ·Biomedical Chromatography ·Hai‐Shu Lin, (unknown), Paul C. Ho	166
16	Histone Deacetylase Inhibitors: New Hope for Rheumatoid Arthritis? 2008 ·Current Pharmaceutical Design ·Qiuyi Choo, Paul C. Ho, Hai‐Shu Lin	50
17	Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding 2006 ·European Journal of Pharmaceutical Sciences ·Jinzhu Wu, Paul C. Ho	92
18	Population Pharmacokinetics of Tacrolimus in Whole Blood and Plasma in Asian Liver Transplant Patients 2006 ·Clinical Pharmacokinetics ·(unknown), Lai Tham, Michael J. Holmes, Marion Aw, Seng Hock Quak, (unknown), Seng Gee Lim, K. Prabhakaran, Sui Yung Chan, Paul C. Ho	62
19	Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins 2005 ·Pharmaceutical Research ·Quan Tian, Jing Zhang, Theresa May Chin Tan, Eli Chan, Wei Duan, Sui Yung Chan, Urs A. Boelsterli, Paul C. Ho, Hongyuan Yang, Jin‐Song Bian, Min Huang, Yi Zhun Zhu, (unknown), Xiaotian Li, Shufeng Zhou	87
20	Stability of cefazolin sodium eye drops 1998 ·Journal of Clinical Pharmacy and Therapeutics ·(unknown), (unknown), (unknown), Lee Yong Lim, (unknown), Paul C. Ho, Sui Yung Chan	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact